Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-Positive Breast Cancer Patients (Stage I, II).

Trial Profile

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-Positive Breast Cancer Patients (Stage I, II).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Anastrozole (Primary) ; Zoledronic acid (Primary) ; Tamoxifen
  • Indications Bone resorption; Breast cancer; Early breast cancer; Osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 03 Aug 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 10 Dec 2011 Results from a pre-specified subgroup analysis presented at the 34th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top